MA5-15556

antibody from Invitrogen Antibodies

Targeting: KDR CD309, FLK1, VEGFR, VEGFR2

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-15556

Provider

Invitrogen Antibodies

Product name

VEGF Receptor 2 Monoclonal Antibody (4B4)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

MA5-15556 targets KDR in FACS, IF, and WB applications and shows reactivity with Human samples.

Antibody clone number

4B4

Concentration

Conc. Not Determined

References

Submitted references

Myocyte Enhancer Factor 2C as a New Player in Human Breast Cancer Brain Metastases.

Galego S, Kauppila LA, Malhó R, Pimentel J, Brito MA
Cells 2021 Feb 12;10(2)

---

Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth.

Sphyris N, King C, Hoar J, Werden SJ, Vijay GV, Miura N, Gaharwar A, Sarkar TR
Oncotarget 2021 Apr 13;12(8):823-844

---

A new algorithm for a better characterization and timing of the anti-VEGF vascular effect named "normalization".

El Alaoui-Lasmaili K, Djermoune EH, Tylcz JB, Meng D, Plénat F, Thomas N, Faivre B
Angiogenesis 2017 Feb;20(1):149-162

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of CD309/VEGFR2 using CD309/VEGFR2 monoclonal antibody (Product # MA5-15556) in extracellular domain of human KDR (aa20-764).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of CD309/VEGFR2 using CD309/VEGFR2 monoclonal antibody (Product # MA5-15556) in extracellular domain of human KDR (aa20-764).

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of HeLa (left) and HepG2 (right) cells using CD309/VEGFR2 monoclonal antibody (Product # MA5-15556) (Green). Blue: DRAQ5 fluorescent DNA dye.

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometric analysis of HepG2 cells using CD309/VEGFR2 monoclonal antibody (Product # MA5-15556) (green) and negative control (purple).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 6 FOXC2 is necessary for the acquisition of endothelial phenotypic and functional characteristics in vitro . ( A ) Immortalized (HMLE) and RAS-transformed (HMLER) human mammary epithelial cells were plated in cell-specific medium. After 24 hours, the cells were treated either with vehicle or desferrioxamine (DFX), a hypoxia-mimetic, for 48 hours prior to fixation and immunostaining for FOXC2 (green) and HIF-1alpha (red). Nuclei were counterstained with DAPI (blue). Right panels are merged images of individual channels. Scale bar: 20 mum. ( B ) HMLE cells, transduced with shRNAs targeting firefly luciferase (shControl) or FOXC2 (shFOXC2), were treated with DFX for 48 hours. Following DFX treatment, the cells were fixed and immunostained for HIF-1alpha (green) and KDR (red). Nuclei were counterstained with DAPI (blue). Right panels are merged images of individual channels. Scale bar: 20 mum ( C ) GFP-labeled HMLE cells (green) were co-mixed with either MDA-MB-231-shControl or MDA-MB-231-shFOXC2 cells and plated onto Matrigel in EGM-2. After 24 hours, the cells were imaged using brightfield (BR) and fluorescence microscopy. Right panels are overlays of brightfield and fluorescent images. The impact of FOXC2 knockdown on the ability of MDA-MB-231 cells to form vascular-like networks and stimulate the incorporation of GFP-labeled HMLE cells into mosaic structures was examined. ( D ) GFP-labeled HMLE cells (green) were co-mixed with either HMLE-Snail-shControl or HMLE-Snail-